Chapter 15 : Treatment of Osteomyelitis and Septic Arthritis

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Treatment of Osteomyelitis and Septic Arthritis, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap15-1.gif /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap15-2.gif


This chapter summarizes the current knowledge of the use of quinolones in the treatment of osteomyelitis and septic arthritis. The identification of the causative organisms of osteomyelitis is essential for diagnosis and treatment. It is important to obtain deep specimens, in particular by bone biopsy, for microbiological and pathological analysis. The specific organism isolated in bacterial osteomyelitis is often associated with the age of the patient, a common clinical presentation (i.e., trauma or recent surgery), and the presence or absence of vascular insufficiency. is found in most patients with acute hematogenous osteomyelitis. , , , ( and ) are commonly isolated in patients with chronic osteomyelitis. The rabbit model of chronic osteomyelitis has the relative advantage of assessing the rate of negative microbiological cultures after 3 to 4 weeks of therapy. Several recent studies show interesting results concerning the potential utilization of quinolones in local drug-carrier systems that allow high local antibiotic concentrations to be achieved. Several recent reviews of the use of various agents in the therapy of osteomyelitis have reported that among the quinolones presently available, ciprofloxacin, ofloxacin, and pefloxacin have been used most often in large series of patients with bacterial osteomyelitis. The combination of quinolones with rifampin for the treatment of staphylococcal osteomyelitis appears promising.

Citation: Bernard L, Waldvogel F, Lew D. 2003. Treatment of Osteomyelitis and Septic Arthritis, p 251-258. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch15
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


1. Bayer, A. S.,, D. Norman,, and D. Anderson. 1985. Efficacy of ciprofloxacin in experimental arthritis caused by Escherichia coli —in vitro-in vivo correlations. J. Infect. Dis. 152: 811 816.
2. Bouchenaki, N.,, P. E. Vaudaux,, E. Huggler,, F. A. Waldvogel,, and D. P. Lew. 1990. Successful single-dose prophylaxis of Staphylococcus aureus foreign body infections in guinea pigs by fleroxacin. Antimicrob. Agents Chemother. 34: 21 24.
3. Bouza, E.,, and P. Munoz. 1999. Micro-organisms responsible for osteoarticular infections. Baillieres Best Pract. Res. Clin. Rheumatol. 13: 21 35.
4. Brouqui, P.,, M. C. Rousseau,, A. Stein,, M. Drancourt,, and D. Raoult. 1995. Treatment of Pseudomonas aeruginosa-'mfect ed orthopedic prostheses with ceftazidime-ciprofloxacin antibiotic combination. Antimicrob. Agents Chemother. 39: 2423 2425.
5. Carek, P. J.,, L. M. Dickerson,, and J. L. Sack. 2001. Diagnosis and management of osteomyelitis. Am. Earn. Physician 63: 2413 2412.
6. Chuard, C., , M. Herrmann,, P. Vaudaux, F. A.,, Waldvogel,, and D. P. Lew. 1991. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob. Agents Chemother. 35: 2611 2616.
7. Cierny, G.,, J. T. Mader,, and H. Pennick. 1985. A clinical staging system of adult osteomyelitis system. Contemp. Orthop. 10: 17 37.
8. Coignard, S.,, C. Renard,, and A. Lortat-Jacob. 1986. Diffusion de la pefloxacine dans le tissu osseux humain. Med. Mai. Infect. 7: 471 474.
9. Cremieux, A. C.,, A. S. Mghir,, R. Bleton,, M. Manteau,, N. Belmatoug,, L. Massias,, L. Garry,, N. Sales,, B. Maziere,, and C. Carbon. 1996. Efficacy of sparfloxacin and autoradiographic diffusion pattern of [1 4C]sparfloxacin in experimental Staphylococcus aureus joint prosthesis infection. Antimicrob. Agents Chemother. 40: 2111 2116.
10. Dan, M.,, Y. Siegman Igra,, S. Pitlik,, and R. Raz. 1990. Oral ciprofloxacin treatment of Pseudomonas aeruginosa osteomyelitis. Antimicrob. Agents Chemother. 34: 849 852.
11. Defino, H. L. A.,, J. E. Moretti,, and A. E. Rodrigues-Fuentes. 1992. Comparative study of the efficacy of pefloxacin versus cephalotin/cephalexin + gentamicin in the treatment of posttraumatic or post-surgical osteomyelitis. Rev. Bras. Med. 49: 785 790.
12. Dellamonica, P.,, E. Bernard,, H. Etesse,, and R. Garraffo. 1986. The diffusion ofpefloxacin into bone and the treatment of osteomyelitis. J. Antimicrob.Chemother. 17( Suppl. B): 93 102.
13. Desplaces, N.,, and J. F. Acar. 1988. New quinolones in thetreatment of joint and bone infections. Rev. Infect. Dis. 10( Suppl.1): S179 S183.
14. Drancourt, M.,, A. Stein,, J. N. Argenson,, A. Zannier,, G. Curvale,, and D. Raoult. 1993. Oral rifampin plus ofloxacin for treatment of Staphylococcus-'mi ected orthopedic implants. Antimicrob. Agents Chemother. 37: 1214 1218.
15. Dworkin, R.,, G. Modin,, S. Kunz,, R. Rich,, O. Zak,, and M. Sande. 1990. Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis. Antimicrob. Agents Chemother. 34: 1014 1016.
16. Fong, I.W.,, W. H. Ledbetter,, A. C. Vandenbroucke,, M. Simbul,, and V. Rahm. 1986. Ciprofloxacin concentrations in bone and muscle after oral dosing. Antimicrob. Agents Chemother. 29: 405 408.
17. Galanakis, N.,, H. Giamarellou,, T. Moussas,, E. Dounis. 1997. Chronic osteomyelitis caused by multi-resistant gram-negative bacteria: evaluation of treatment with newer quinolones after prolonged follow-up. J. Antimicrob. Chemother. 39: 241 246.
18. Garcia Rosario, L. N.,, and C. H. Ramirez Ronda. 1990. The use of ciprofloxacin in patients with osteomyelitis associated with vascular insufficiency. Bol. Assoc. Med. P. R. 82: 125 128.
19. Gentry, L. O.,, and G. G. Rodriguez. 1990. Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. Antimicrob. Agents Chemother. 34: 40 43.
20. Gentry, L. O. 1991. Oral antimicrobial therapy for osteomyelitis. Ann. Intern. Med. 114: 986 987.
21. Gentry, L. O.,, and G. G. Rodriguez. 1991. Ofloxacin versus parenteral therapy for chronic osteomyelitis. Antimicrob. Agents Chemother. 35: 538 541.
22. Gilbert, D. N.,, A. D. Tice,, P. K. Marsh,, P. C. Craven,, and L. C. Preheim. 1987. Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli. Am. J. Med. 82: 254 258.
23. Gomis, M.,, J . Barberan,, B. Sanchez,, S. Khorrami,, J . Borja,, and J . Garcia-Barbal. 1999. Oral ofloxacin versus parenteral imipenem-cilastatin in the treatment of osteomyelitis. Rev. Esp. Quimioter 12: 244 9.
24. Greenberg, R. N.,, D. J . Kennedy,, P. M. Reilly,, K. L. Luppen,, W. J . Weinandt,, M. R. Bollinger,, F. Aguirre,, F. Kodesch,, A. M. Saeed. 1987. Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin. Antimicrob. Agents Chemother. 31: 151 155.
25. Greenberg, R. N.,, M. T. Newman,, S. Shariaty,, and R. W. Pectol. 2000. Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis. Antimicrob. Agents Chemother. 44: 164 166.
26. Greenberg, R. N.,, A. D. Tice,, P. K. Marsh,, P. C. Craven,, P. M. Reilly,, M. Bollinger,, and W. J. Weinandt. 1987. Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis. Am. J. Med. 82: 266 269.
27. Henry, N. K.,, M. S. Rouse,, A. L. Whitesell,, M. E. McConnell,, and W. R. Wilson. 1987. Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin. Am. J. Med. 82: 73 75.
28. Hessen, M. T.,, M. J . Ingerman,, D. H. Kaufman,, M. T. Hessen,, M. J. Ingerman,, D. H. Kaufman,, P. Weiner,, J . Santoro,, O. M. Korzeniowski,, J . Boscia,, M. Topiel,, L. M. Bush,, and D. Kaye.. 1987. Clinical efficacy of ciprofloxacin therapy for gram-negative bacillary osteomyelitis. Am. J. Med. 82: 262 265.
29. Hessen, M. T.,, and M. E. Levison. 1989. Ciprofloxacin for the treatment of osteomyelitis: a review. J. Foot Surg. 28: 100 105.
30. Hoogkamp-Korstanje, J. A.,, H. A. van Bottenburg,, J . van Bruggen,, J. S. Davidson,, S. J. Detmar,, W. de Graaf,, J. Rijnks,, J. F. Ypma,, D. F. de Zwart. 1989. Treatment of chronic osteomyelitis with ciprofloxacin. J. Antimicrob. Chemother. 23: 427- 432.
31. Huddleston, P. M.,, J. M. Steckelberg,, A. D. Hanssen,, M. S. Rouse,, M. E. Bolander,, and R. Patel. 2000. Ciprofloxacin inhibition of experimental fracture healing. J. Bone Joint Surg. 82: 161 173.
32. Kanellakopoulou, K.,, N. Galanakis,, E. J. Giamarellos- Bourboulis,, C. Rifiotis,, K. Papakostas,, A. Andreopoulos,, E. Dounis,, P. Karagianakos,, H. Giamarellou. 2000. Treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with a biodegradable system of lactic acid polymer releasing pefloxacin. J. Antimicrob. Chemother. 46: 311 314.
33. Ketterl, R.,, T. Beckurts,, B. Stubinger,, and B. Claudi. 1988. Use of ofloxacin in openfractures and in the treatment of posttraumatic osteomyelitis. J.Antimicrob. Chemother. 22( SupplC): S159 S166.
34. Ketterl, R.,, W. Wittwer,, and T. Beckurts. 1995. Ofloxacin zur antibiotikatherapie bei der chronischen posttraumatischen Osteitis. Med. Welt. 46: 505 511.
35. Lew, D.P.,, and F. A. Waldvogel,. 1993. , p. 371 379. In D. C. Hooper, and J. S. Wolfson (ed.), Quinolone Antimicrobial Agents, 2nd ed. American Society for Microbiology, Washington, D.C.
36. Lew, D.P.,, and F. A. Waldvogel. 1999. Quinolones andosteomyelitis: state-of-the-art. Drugs. 4958( Suppl. 2): S85100 S91110.
37. Lew, D. P.,, and F. A. Waldvogel. 1997. Osteomyelitis. N. Engl. J. Med. 336: 999 1007.
38. Lipsky, B. A.,, P. D. Baker,, G. C. Landon,, and R. Fernau. 1997. Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens. Clin. Infect. Dis. 24: 643 648.
39. Lipsky, B. A. 1997. Osteomyelitis of the foot in diabetic patients. Clin. Infect. Dis. 25: 1318 1326.
40. Lucet, J. C.,, M. Herrmann,, P. Rohner,, R. Auckenthaler,, F. A. Waldvogel,, and D. P. Lew. 1990. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 34: 2312 2317.
41. Mader, J. T.,, J. S. Cantrell,, and J . Calhoun. 1990. Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults. J. Bone Joint Surg. 72: 104 110.
42. Mader, J.T.,, C. Norden,, J . D. Nelson,, and G. B. Calandra. 1992. Evaluation of new anti-infective drugs for the treatment of osteomyelitis in adults. Infectious Diseases Society of America and the Food and Drug Administration. Clin. Infect. Dis. 15( Suppl. 1): S155 S16.
43. Meissner, A.,, and K. Borner. 1993. Konzentration von Ciprofloxacin im Knochengewebe Concentration of Ciproloxacin in Bone Tissue. Akt. Traumatol. 23: 80 84.
44. Meissner, A.,, K. Borner,, and P. Koeppe. 1990. Concentrations of ofloxacin in human bone and in cartilage. J. Antimicrob. Chemother. 26( Suppl. D: 69 74.
45. Monzon, M.,, F. Garcia-Alvarez,, A. Lacleriga,, E. Gracia,, J . Leiva,, C. Oteiza,, and B. Amorena. 2001. A simple infection model using pre-colonized implants to reproduce rat chronic Staphylococcus aureus osteomyelitis and study antibiotic treatment. J. Orthop. Res. 19: 820 826.
46. Nicolau, D. P.,, L. Nie,, P. R. Tessier,, H. P. Kourea,, and C. H. Nightingale. 1998. Prophylaxis of acute osteomyelitis with asorbable ofloxacin-impregnated beads. Antimicrob. Agents Chemother. 42: 840 842.
47. Nie, L.,, D. P. Nicolau,, P. R. Tessier,, H. P. Kourea,, B. D. Browner,, and C. H. Nightingale. 1998. Use of a bioabsorbable polymer for the delivery of ofloxacin during experimental osteomyelitis treatment. J. Orthop. Res. 16: 76 79.
48. Nix, D. E.,, T. J. Cumbo,, P. Kuritzky,, J. M. DeVito,, J. J. Schentag. 1987. Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics. Am. J. Med. 82: 146 153.
49. Norden, C.,, J. D.Nelson,, J. T. Mader,, and G. B. C alandra. 1992. Evaluation of new anti-infective drugs for the treatment of infectious arthritis in adults. Infectious Diseases Society of America and the Food and Drug Administration. Clin. Infect. Dis. 15( Suppl. 1): S167 S171.
50. Norden, C. W.,, and E. Stunners. 1995. Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa. J. Infect. Dis. 151: 291 294.
51. Norrby, S.R. 1989. Ciprofloxacin in the treatment ofacute and chronic osteomyelitis: a review. Scand. J Infect. Dis.Suppl. 60( Suppl.): S74 S78.
52. Ortega, M.,, A. Soriano,, S. Garcia,, M. Almela,, J. L. Alvarez,, X. Tomas,, J . Mensa,, and E. Soriano. 2000. Tolerability and safety of levofloxacin long-term treatment. Rev. Esp. Quimioter 13: 263 266.
53. Patzakis, M. J.,, R. S. Bains,, J. Lee,, L. Shepherd,, G. Singer,, R. Ressler,, F. Harvey,, and P. Holtom. 2000. Prospective, randomized, double-blind study comparing single-agent antibiotic therapy, ciprofloxacin, to combination antibiotic therapy in open fracture wounds. J. Orthop. Trauma. 14: 529 533.
54. Peterson, L. R.,, L. M. Lissack,, K. Canter,, C. E. Fasching,, C. Clabots,, D. N. Gerding. 1989. Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both. Am. J. Med. 86: 801 808.
55. Rissing, J. P. 1997. Antimicrobial therapy for chronic osteomyelitis in adults: role of the quinolones. Clin. Infect. Dis. 25: 1327 1333.
56. Schlichting, C.,, C. Branger,, J. M. Fournier,, W. Witte,, A. Boutonnier,, C. Wolz,, P. Goullet,, and G. Doring. 1993. Typing of Staphylococcus aureus by pulsed-field gel electrophoresis, zymotyping, capsular typing, and phage typing: resolution of clonal relationships. J. Clin. Microbiol. 31: 227 232.
57. Seibold, R.,, and A. Betz. 1991. Treatment of posttraumatic osteitis with intravenous ofloxacin. Clin. Ther. 13: 457 459.
58. Shirtliff, M. E.,, J. H. Calhoun,, and J. T. Mader. 2001. Comparative evaluation of oral levofloxacin and parenteral nafcillin in the treatment of experimental methicillin-susceptible Staphylococcus aureus osteomyelitis in rabbits. J. Antimicrob. Chemother. 48: 253 258.
59.SwedisStudyGroup. 1988. Therapy of acute and chronic gram-negative osteomyelitis withciprofloxacin. J. Antimicrob. Chemother. 22: 221228.
60. Trujillo, I.Z.,, G. Valladares,, and A. Nava. 1993. Ciprofloxacin in the treatment of chronic osteomyelitis in adults. Drugs 45( Suppl. 3): S454 S455.
61. Waldvogel, F.A. 1989. Use of quinolones for the treatmentof osteomyelitis and septic arthritis. Rev. Infect. Dis. 11: S1259 S1263
62. Waldvogel, F. A.,, G. Medoff,, and M. N. Swartz. 1970. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. N. Engl. J. Med. 29: 260 6.
63. Widmer, A. F.,, A. Gaechter,, P. E. Ochsner,, and W. Zimmerli. 1992. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin. Infect. Dis. 14: 1251 1253.
64. Wispelwey, B.,, and W. M. Scheld. 1990. Ciprofloxacin in the treatment of Staphylococcus aureus osteomyelitis. A review. Diagn. Microbiol. Infect. Dis. 13: 169 171.
65. Wittmann, D.H.,, and E. Kotthaus. 1986. Further methodological improvement in antibiotic bone concentration measurements: penetration of ofloxacin into bone and cartilage. Infection 14( Suppl. 4): S270 S273
66. Yamaguti, A.,, C. Trevisanello,, I. M. Lobo,, M. C. Carvano,, M. L. Bortoletto,, M. L. Silva,, R. Brasil Filho,, G. C. Levi,, and J . S. Mendonca. 1993. Oral ciprofloxacin for treatment of chronic osteomyelitis. Int. J. Clin. Pharmacol. Res. 13: 75 79.
67. Zimmerli, W.,, A. F. Widmer,, M. Blatter,, R. Frei,, P. E. Ochsner. 1998. Foreign-body infection (FBI) study group. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections—a randomized controlled trial. JAMA 279: 1537 1541.


Generic image for table
Table 1

Spectrum of microorganisms responsible for osteomyelitis in adults

Citation: Bernard L, Waldvogel F, Lew D. 2003. Treatment of Osteomyelitis and Septic Arthritis, p 251-258. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch15

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error